Miscellaneous immune disorders:
Indications for: RUZURGI
Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to <17yrs of age.
<6yrs: not established. 6–<17yrs: (≥45kg): initially 15–30mg daily in 2–3 divided doses, may increase daily by 5–10mg increments, divided in up to 5 doses; max single dose: 30mg; max total maintenance 100mg/day; (<45kg): initially 7.5–15mg daily in 2–3 divided doses, may increase daily by 2.5–5mg increments, divided in up to 5 doses; max single dose: 15mg; max total maintenance 50mg/day. Hepatic or renal impairment (CrCl 15–90mL/min), NAT2 poor metabolizers: (≥45kg): initially 15mg daily in divided doses; (<45kg): initially 7.5mg daily in divided doses.
History of seizures.
Consider dose reduction or discontinuation if seizure occurs. Discontinue and treat if anaphylaxis occurs. Hepatic or renal impairment: monitor; adjust dose or discontinue as needed. N-acetyltransferase 2 (NAT2) poor metabolizers. Pregnancy. Nursing mothers.
Potassium channel blocker.
Concomitant drugs that lower seizure threshold may increase seizure risk. Additive effects when concomitant drugs with cholinergic effects (eg, direct or indirect cholinesterase inhibitors).
Paresthesia/dysesthesia, abdominal pain, dyspepsia, dizziness, nausea; seizures, hypersensitivity.
Generic Drug Availability: